Charisse Kemp

Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers

Sujata Vaidyanathan, Jessica Valencia, Charisse Kemp et al. · International Journal of Clinical Practice · 2006 · 87 citations

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian et al. · Haematologica · 2014 · 48 citations · Full text

ENESTnd Update: Nilotinib (NIL) Vs Imatinib (IM) In Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) and The Impact Of Early Molecular Response (EMR) and Sokal Risk At Diagnosis On Long-Term Outcomes

Giuseppe Saglio, Andreas Hochhaus, Timothy P. Hughes et al. · Blood · 2013 · 47 citations

Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hagop M. Kantarjian, Dong-Wook Kim, Surapol Issaragrisil et al. · Blood · 2012 · 37 citations

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Andreas Hochhaus, Timothy P. Hughes, Giuseppe Saglio et al. · Blood · 2012 · 34 citations